PILOT STUDY OF EGFR INHIBITION WITH ERLOTINIB IN CIRRHOSIS TO INHIBIT FIRBROGENESIS AND PREVENT HEPATOCELLULAR CARCINOMA HHSN261201200042I; TASK ORDER HHSN26

Project: Research project

Project Details

Description

The proposed Pilot, dose ranging clinical trial is designed to identify the lowest safe and minimum effective dose (MED) of daily erlotinib that inhibits epidermal growth factor receptor (EGFR) signaling in the target organ (liver) as assessed by phospho?EGFR staining. Epidermal growth factor (EGF) expression is associated with progression of cirrhosis, and in animal models, overexpression of EGF in liver tissue leads to formation of hepatocellular carcinoma
StatusNot started

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.